BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35563753)

  • 1. B7-H4 Immune Checkpoint Protein Affects Viability and Targeted Therapy of Renal Cancer Cells.
    Emaldi M; Nunes-Xavier CE
    Cells; 2022 Apr; 11(9):. PubMed ID: 35563753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
    Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
    Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
    Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mifepristone inhibited the expression of B7-H2, B7-H3, B7-H4 and PD-L2 in adenomyosis.
    Qin X; Sun W; Wang C; Li M; Zhao X; Li C; Zhang H
    Reprod Biol Endocrinol; 2021 Jul; 19(1):114. PubMed ID: 34289871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Genova C; Tasso R; Rosa A; Rossi G; Reverberi D; Fontana V; Marconi S; Croce M; Dal Bello MG; Dellepiane C; Tagliamento M; Ciferri MC; Zullo L; Fedeli A; Alama A; Cortese K; Gentili C; Cella E; Anselmi G; Mora M; Barletta G; Rijavec E; Grossi F; Pronzato P; Coco S
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer.
    Yang J; Tian Z; Gao H; Xiong F; Cao C; Yu J; Shi W; Zhan Q; Yang C
    BMC Cancer; 2022 May; 22(1):584. PubMed ID: 35624419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of blocking novel immune checkpoint B7-H4 in urothelial carcinoma of bladder as a potential therapeutic target.
    Raja D; Singh A; Kurra S; Nayak B; Kaushal S; Sharma A; Singh P
    Med Oncol; 2024 Feb; 41(3):74. PubMed ID: 38376603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
    Nunes-Xavier CE; Kildal W; Kleppe A; Danielsen HE; Waehre H; Llarena R; Maelandsmo GM; Fodstad Ø; Pulido R; López JI
    Prostate; 2021 Sep; 81(12):838-848. PubMed ID: 34125445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma.
    Lu Z; Zhao ZX; Cheng P; Huang F; Guan X; Zhang MG; Chen HP; Liu Z; Jiang Z; Zheng ZX; Zou SM; Wang XS
    Mod Pathol; 2020 Nov; 33(11):2330-2340. PubMed ID: 32514163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer.
    Cherif B; Triki H; Charfi S; Bouzidi L; Kridis WB; Khanfir A; Chaabane K; Sellami-Boudawara T; Rebai A
    Sci Rep; 2021 Apr; 11(1):7550. PubMed ID: 33824367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer.
    Liu Z; Jin K; Zeng H; Shao F; Chang Y; Wang Y; Xu L; Wang Z; Cui X; Zhu Y; Xu J
    Eur J Cancer; 2022 Aug; 171():133-142. PubMed ID: 35717821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
    MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
    J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC.
    Thomas PL; Groves SM; Zhang YK; Li J; Gonzalez-Ericsson P; Sivagnanam S; Betts CB; Chen HC; Liu Q; Lowe C; Chen H; Boyd KL; Kopparapu PR; Yan Y; Coussens LM; Quaranta V; Tyson DR; Iams W; Lovly CM
    J Thorac Oncol; 2021 Jul; 16(7):1211-1223. PubMed ID: 33839362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy?
    Zhang W; Qiu Y; Xie X; Fu Y; Wang L; Cai Z
    Front Oncol; 2021; 11():647526. PubMed ID: 33869045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment.
    Bolandi N; Derakhshani A; Hemmat N; Baghbanzadeh A; Asadzadeh Z; Afrashteh Nour M; Brunetti O; Bernardini R; Silvestris N; Baradaran B
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression.
    Lu Y; Wu F; Cao Q; Sun Y; Huang M; Xiao J; Zhou B; Zhang L
    Oncogene; 2022 Jan; 41(5):704-717. PubMed ID: 34839353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
    Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
    Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
    [No Abstract]   [Full Text] [Related]  

  • 18. B7 family protein glycosylation: Promising novel targets in tumor treatment.
    Xiao L; Guan X; Xiang M; Wang Q; Long Q; Yue C; Chen L; Liu J; Liao C
    Front Immunol; 2022; 13():1088560. PubMed ID: 36561746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.
    Genova C; Boccardo S; Mora M; Rijavec E; Biello F; Rossi G; Tagliamento M; Dal Bello MG; Coco S; Alama A; Vanni I; Barletta G; Bianchi R; Maggioni C; Bruzzi P; Grossi F
    J Clin Med; 2019 Oct; 8(10):. PubMed ID: 31581482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative immune checkpoints in immunoregulatory profile of cancer stem cells.
    Mortezaee K; Majidpoor J
    Heliyon; 2023 Dec; 9(12):e23171. PubMed ID: 38144305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.